Additionally, targeting specific CAF subpopulations associated with treatment resistance, such as CD10+GPR77+ CAFs, can not only effectively inhibit tumor growth, but also restore tumor sensitivity to chemotherapy, representing a highly promising new therapeutic direction [180]. This evidence concerns the gene MME and neoplasm.